Background Adjuvant chemotherapy improves survival in premenopausal and
postmenopausal women with early breast cancer. Taxanes are highly active chemotherapy …

Breast cancer is the most commonly diagnosed cancer in American women and is the
second leading cause of cancer‐related deaths in this population. This review highlights …

Background Ovarian suppression plus tamoxifen is a standard adjuvant treatment in
premenopausal women with endocrine-responsive breast cancer. Aromatase inhibitors are …

BACKGROUND: Population‐based studies have shown improved survival for patients
diagnosed with metastatic breast cancer over time, presumably because of the availability of …

Ziele Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für
Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) …

Background A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior
to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as …

Background In five randomized clinical trials (RCTs), adjuvant trastuzumab (T) for early
stage breast cancer with human epidermal growth-factor receptor-2 over-expression/gene …

We evaluated the effect of low doses of systemically administered tetrodotoxin (TTX) on the
development and expression of neuropathic pain induced by paclitaxel in mice. Treatment …

To identify a group of patients who might benefit from the addition of weekly paclitaxel to
conventional anthracycline-containing chemotherapy as adjuvant therapy of node-positive …

Background: Paclitaxel and docetaxel are considered fundamental drugs in the treatment of
breast cancer. Objectives: To review the current role of taxanes in the treatment breast …